Bioceltix S.A. (WSE:BCX)
Poland · Delayed Price · Currency is PLN 80.00
-0.60 (-0.74%)
Aug 14, 2026, 5:01 PM CET
Bioceltix Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
46
Market Cap
442.58M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 0 | - | - |
| Dec 31, 2024 | 0 | - | - |
| Dec 31, 2023 | 0 | - | - |
| Dec 31, 2022 | 0 | - | - |
| Dec 31, 2021 | 0 | - | - |
| Dec 31, 2020 | 10.80K | 9.30K | 620.00% |
| Dec 31, 2019 | 1.50K | -7.70K | -83.70% |
| Dec 31, 2018 | 9.20K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| BIOTON | 266.02M |
| Ryvu Therapeutics | 88.38M |
| Synthaverse | 42.19M |
| Mabion | 17.61M |
| Molecure | 6.52M |
| Urteste | 2.50M |
| Captor Therapeutics Spolka Akcyjna | 2.38M |
| Pharmena | 1.61M |
Bioceltix News
- 2 months ago - Bioceltix Quarterly report: Q1 2026 - Filings
- 3 months ago - Bioceltix Annual report: Q4 2025 - Filings
- 4 months ago - Bioceltix Slides: Company presentation - Filings
- 7 months ago - Certain BlackRock Closed-End Funds Announce Estimated Sources of Distributions - Business Wire
- 9 months ago - Bioceltix Quarterly report: Q3 2025 - Filings
- 10 months ago - 5 High Yield CEFs With Steep Discounts Right Now - Forbes
- 11 months ago - Bioceltix Quarterly report: Q2 2025 - Filings
- 1 year ago - Certain BlackRock Sector Equity Closed-End Funds Announce Updates to Investment Objectives and Principal Investment Strategies - Business Wire